Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer
BLACKHAWK, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles and a proposed de-SPAC acquisition target for Black Hawk Acquisition Corporation (NASDAQ:BKHA, BKHAU, BKHAR)), today announced that its Board of Directors has appointed Michael Tolentino, M.D., an accomplished biotech leader with deep industry experience, as Chief Executive Officer (CEO), effective March 17, 2026. He succeeds Founder and CEO Luo Feng, Ph.D., who has been appointed Chief Scientific Officer.
"Dr. Tolentino is an exceptional leader whose biotech industry expertise, deep relationships across the contract r
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.